Treatment of murine testicular leukemia.
The murine leukemia P388 is being evaluated as a potential model for testicular leukemia since this tumor is responsive to most of the drugs used to treat childhood acute lymphocytic leukemia. Infiltration of P388 cells into testes occurs, but the tumor cells plateau at about 10(5) to 10(6) cells/testes, a number inadequate to produce macroscopic disease. Therefore, disease could be evaluated only by bioassay, i.e., suspending and implanting the testes into recipient mice. In advanced disease (at plateau), the tumor cells are responsive to Adriamycin; when the tumor cells are proliferating in testes, they respond to treatment with Adriamycin, methotrexate, and vincristine. Therefore, in this model, the testicular leukemia cells do not appear to reside in a pharmacological sanctuary.
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage; D007941:Leukemia P388 / Q000188:drug therapy*; D007942:Leukemia, Experimental / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D051379:Mice; D008811:Mice, Inbred DBA; D013736:Testicular Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D004317:Doxorubicin; D008727:Methotrexate